Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply with High Purity and Stable Quality Chemical Name: Lasofoxifene Tartrate CAS: 190791-29-8 Lasofoxifene Tartrate (CAS: 190791-29-8) in the treatment of Postmenopausal Osteoporosis| Item | Specifications |
| Appearance | White to Off-White Powder |
| Moisture (K.F) | ≤0.50% |
| Heavy Metals | ≤20ppm |
| Chiral Purity | ≥99.0% |
| Purity / Analysis Method | ≥98.0% (HPLC) |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.50% |
| Test Standard | Chinese Pharmacopoeia (CP); Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API); Postmenopausal Osteoporosis |
Description:
Specifications:
Package & Storage:
| Chemical Name | Lasofoxifene Tartrate |
| Synonyms | (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol Tartrate Oporia |
| CAS Number | 190791-29-8 |
| CAT Number | RF-API20 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C28H31NO2.ClH |
| Molecular Weight | 450.019 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Lasofoxifene Tartrate (CAS: 190791-29-8) with high quality. Lasofoxifene Tartrate is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). It selectively binds to human ERalpha with an IC50 value of 1.5 nM and inhibits bone loss in ovariectomized rats. In clinical studies of postmenopausal osteoporosis, 0.5 mg/day lasofoxifene was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. Lasofoxifene has also been shown to act as an inverse agonist at the CB2 cannabinoid receptor, indicating its potential to be repurposed as a therapeutic for indications wherein CB2 is a target.
